Jazz Pharmaceuticals plc (JAZZ)
| Market Cap | 7.43B |
| Revenue (ttm) | 3.99B |
| Net Income (ttm) | 463.16M |
| Shares Out | 60.45M |
| EPS (ttm) | 7.04 |
| PE Ratio | 17.48 |
| Forward PE | 5.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,767,343 |
| Open | 122.85 |
| Previous Close | 122.85 |
| Day's Range | 121.37 - 124.39 |
| 52-Week Range | 99.06 - 134.17 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 173.93 (+41.44%) |
| Earnings Date | Nov 6, 2024 |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is $173.93, which is an increase of 41.44% from the latest price.
News
Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
DUBLIN , Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Confer...
Jazz Pharmaceuticals Announces CEO Succession Plan
Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Fo...
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting
Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests improv...
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)
Ziihera, the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC, is now commercially available in the United States For U.S. media and investors only DUBLIN , De...
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024
DUBLIN , Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m.
Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting
Data showcased at SABCS and ASH reflect progress and growth of Jazz's research and development in oncology and demonstrate ongoing efforts to redefine what is possible for cancer treatment DUBLIN , De...
Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of biliary tract cancer, the company said on Wednesday.
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate a...
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
DUBLIN , Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will pa...
Jazz Pharmaceuticals plc (JAZZ) Q3 2024 Earnings Call Transcript
Jazz Pharmaceuticals plc (JAZZ) Q3 2024 Earnings Call Transcript
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
Jazz Pharmaceuticals plc JAZZ reported record third-quarter revenue of $1.05 billion on Wednesday afternoon, up 14% year-over-year, propelled by strong sales of key therapies like Xywav, Epidiolex and...
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
– 14% year-over-year revenue increase from combined key growth drivers:Xywav®, Epidiolex® and Rylaze® –– 2024 total revenue guidance affirmed at $4.0 to $4.1 billion –– Zanidatamab 2L BTC PDUFA date o...
Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia
First presentation of top-line efficacy and safety results from the Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial of adults with narcolepsy or idiop...
Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
DUBLIN , Oct. 23, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 third quarter financial results on Wednesday, November 6, 2024, after the cl...
Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. The partial legal win against Avadel helps protect Jazz's market position in idiopath...
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Jazz Pharmaceuticals plc JAZZ revealed topline results from the Phase 3 clinical trial evaluating Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor Roche Holdings AG's RHHBY atezolizuma...
Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Jazz plans to submit supplemental New Drug Application in first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC DUBLIN , Oct. 15, 2024 /PRNewswire/ -- Jazz ...
Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer Market
Jazz Pharmaceuticals (JAZZ, Financial), a leading player in the narcolepsy market, is expanding its reach into other markets such as the non-small cell lung cancer (NSCLC) market by preparing a new bi...
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Phase 2 updated results for zanidatamab in HER2-positive mGEA included a confirmed objective response rate (cORR) of 84%, duration of response (DoR) of 18.7 months, median progression-free survival (m...
Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
New and updated data from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for first-line treatment of HER2-positive...
Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024
Data from eight abstracts to be presented, including results of the BECOME (BEhavior, COgnition and More with Epidyolex®) Caregiver Survey on the real-world outcomes of Epidyolex® (cannabidiol) treatm...
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
DUBLIN , Sept. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 3.125% exchangeable se...
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
DUBLIN , Sept. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), int...
Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies
DUBLIN , Aug. 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 open-label, single-arm trial in Japan evaluating the safety and efficac...
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
DUBLIN , Aug. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Wells Fargo Healthcare Co...